Mezzion Pharma Co., Ltd. Logo

Mezzion Pharma Co., Ltd.

Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.

140410 | KO

Overview

Corporate Details

ISIN(s):
KR7140410002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics, with a particular emphasis on rare diseases. The company's primary efforts are centered on its drug candidate, udenafil, for various medical conditions. A key initiative is the development of udenafil for adolescents living with Fontan circulation, a rare congenital heart condition, supported by a large-scale Phase 3 clinical trial (FUEL-2). Mezzion's pipeline also includes potential treatments for pulmonary arterial hypertension (PAH), portal hypertension, and erectile dysfunction. The company's business model involves developing pharmaceutical products and out-licensing them for international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.9 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 101.3 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 107.8 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 67.0 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 94.9 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 972.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.7 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 143.7 KB

Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mezzion Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.